How does the lack of a placebo arm affect the interpretation of results in an open-label trial?

May 29, 2024 ... Infusion of mbIL-7-TIL has acceptable safety and potent efficacy in recurrent OC patients who have limited treatment options. Jul 9, 2021 ... Phase 1b open-label trial of afatinib plus Xentuzumab (BI 836845) in patients with EGFR mutation-positive NSCLC after progression on EGFR tyrosine kinase ... A randomized, multicenter, open-label trial to determine peritonitis rate, product defect, and technique survival between ANDY-Disc® and UltraBag® in patients ... Nitazoxanide co-administered with atazanavir/ritonavir was safe but not better than standard of care in treating COVID-19. This is a first-in-human, Ph 1/2, open-label, multicenter dose escalation and expansion study in advanced solid tumors. The objective of this investigation is to assess the efficacy of coenzyme Q10 as a preventive treatment for migraine headaches. Official Title. A Phase 2/3, Multicenter, Open-label Trial to Evaluate the Long-term Safety, Tolerability, and Efficacy of Sibeprenlimab Administered ... Triheptanoin dramatically reduced by 90% the number of non-epileptic paroxysmal manifestations over 2 months in GLUT1-DS and improved patient's brain energy ... A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope. Open-label studies lack the rigor of blinded studies. Since the lack of blinding can introduce significant bias, reserve the use of open-label studies for ...